There are currently 172 clinical trials in Toledo, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Toledo, Toledo Hospital, ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital and Toledo Clinic Cancer Centers-Toledo. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162
Recruiting
This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to other places in the body (advanced). The second part of this study will also help to find out if the cisplatin given weekly approach will extend patients' life by at least the same amount of time as the cisplatin given every three weeks approach. Cisplatin is in a class... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio
Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: ProMedica Health Systems, Toledo, Ohio +1 locations
Conditions: Heart Failure
Register for Updates
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177
Recruiting
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Toledo Clinic Cancer Center, Toledo, Ohio
Conditions: Colorectal Cancer
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Toledo Institute of Clinical Research, Toledo, Ohio
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT05896189
Recruiting
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: Mercy Health - Saint Vincent Hospital, Toledo, Ohio +2 locations
Conditions: Breast Cancer, Cognitive Impairments
Register for Updates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Mercy Health - Saint Vincent Hospital, Toledo, Ohio +2 locations
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Medtronic Terminate AF Study
NCT03546374
Recruiting
The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal AF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: ProMedica Toledo, Toledo, Ohio
Conditions: Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Register for Updates
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT05951179
Recruiting
TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and anti-tumor activity of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Toledo, Toledo, Ohio
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/22/2025
Locations: Research Site, Toledo, Ohio
Conditions: Acute Coronary Syndrome
Register for Updates
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093
Recruiting
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2025
Locations: Research Site, Toledo, Ohio +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio +1 locations
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974
Recruiting
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Gender:
ALL
Ages:
Between 18 years and 83 years
Trial Updated:
04/10/2025
Locations: Toledo, Toledo, Ohio
Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Register for Updates